Krystal Biotech (KRYS) reported third-quarter earnings per share of 91 cents, which beat the Zacks Consensus Estimate of 84 cents. In the year-ago quarter, the company incurred a loss of 67 cents per share.Revenues totaled $83.8 million, which beat the Zacks Consensus Estimate of $83 million. Revenues came in solely from the sales of Vyjuvek. In the year-ago quarter, revenues amounted to $8.6 million.Shares of Krystal have surged 37.8% year to date against the industry’s decline of 3.8%.Image Source: Zacks ...